Innoviva Inc (INVA) 11.38 $INVA
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (-0.08), INVA: 11.38 (-0.02), GWPH: 93.47 (+0.54), UTHR: 109.58 (-0.59)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.38 (-0.02), PFE: 35.77 (-0.09), SNY: 40.99 (-0.24), REGN: 371.45 (-0.12)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.38 (-0.02), PFE: 35.77 (-0.09), BMY: 74.08 (+0.22)
Alnylam Stock Up on Favorable Patisiran and Revusiran Data
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:02AM CDT
Alnylam Pharmaceuticals' (ALNY) shares jumped 10.7% after the company reported new data from the ongoing studies on patisiran and revusiran.
ALNY: 61.52 (+1.09), INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), PFE: 35.77 (-0.09)
Integra LifeSciences at 52-Week High on Solid Q1 Results
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 7:32AM CDT
Integra Lifesciences (IART)has a market cap of $2.98 billion and a long-term expected earnings growth rate of 11.86%.
IART: 80.86 (+1.60), INVA: 11.38 (-0.02), FCSC: 1.18 (-0.05), ANIP: 58.12 (+0.59)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 30.88 (-0.51), TSRO: 91.96 (+1.70), HSKA: 41.19 (+0.71), INVA: 11.38 (-0.02)
Anavex Life Sciences (AVXL) in Focus: Stock Rises 16.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:25AM CDT
Anavex Life Sciences Corp. (AVXL) moved big last session, as its shares jumped over 16% on the day.
AVXL: 6.94 (+0.64), INVA: 11.38 (-0.02)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.38 (-0.02), TBPH: 23.00 (+0.05), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Technical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva
PR Newswire - Thu Jun 09, 8:05AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Fortinet Inc. (NASDAQ: FTNT), Workday Inc. (NYSE: WDAY), Proofpoint Inc. (NASDAQ: PFPT), and Innoviva Inc. (NASDAQ: INVA). Learn more about these stocks by accessing their free trade alerts at:
PFPT: 64.66 (+0.53), INVA: 11.38 (-0.02), WDAY: 73.79 (+1.19), FTNT: 32.10 (+0.42)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.38 (-0.02), TBPH: 23.00 (+0.05), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.38 (-0.02)
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks Equity Research - Zacks Investment Research - Wed May 25, 10:21AM CDT
GlaxoSmithKline (GSK) and partner Innoviva reported positive headline data from a phase IIIb chronic obstructive pulmonary disease study on Relvar Ellipta.
INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'
Marketwire Canada - Tue May 24, 5:01AM CDT
Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:14AM CDT
Glaxo (GSK) and Innoviva (INVA) have announced results of two pre-specified analyses from the SUMMIT study on Breo Ellipta.
INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI'
in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy.
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (-0.08), INVA: 11.38 (-0.02), GWPH: 93.47 (+0.54), UTHR: 109.58 (-0.59)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.38 (-0.02), PFE: 35.77 (-0.09), SNY: 40.99 (-0.24), REGN: 371.45 (-0.12)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.38 (-0.02), PFE: 35.77 (-0.09), BMY: 74.08 (+0.22)
Alnylam Stock Up on Favorable Patisiran and Revusiran Data
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:02AM CDT
Alnylam Pharmaceuticals' (ALNY) shares jumped 10.7% after the company reported new data from the ongoing studies on patisiran and revusiran.
ALNY: 61.52 (+1.09), INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), PFE: 35.77 (-0.09)
Integra LifeSciences at 52-Week High on Solid Q1 Results
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 7:32AM CDT
Integra Lifesciences (IART)has a market cap of $2.98 billion and a long-term expected earnings growth rate of 11.86%.
IART: 80.86 (+1.60), INVA: 11.38 (-0.02), FCSC: 1.18 (-0.05), ANIP: 58.12 (+0.59)
Myriad Genetics myChoice Cancer Test Findings Encourage
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:34AM CDT
With respect to myChoice HRD test, Myriad earlier noted that it expects to serve a worldwide market size of $18.5 billion (compared with the current market size of $5.6 billion).
MYGN: 30.88 (-0.51), TSRO: 91.96 (+1.70), HSKA: 41.19 (+0.71), INVA: 11.38 (-0.02)
Anavex Life Sciences (AVXL) in Focus: Stock Rises 16.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:25AM CDT
Anavex Life Sciences Corp. (AVXL) moved big last session, as its shares jumped over 16% on the day.
AVXL: 6.94 (+0.64), INVA: 11.38 (-0.02)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.38 (-0.02), TBPH: 23.00 (+0.05), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Technical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva
PR Newswire - Thu Jun 09, 8:05AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Fortinet Inc. (NASDAQ: FTNT), Workday Inc. (NYSE: WDAY), Proofpoint Inc. (NASDAQ: PFPT), and Innoviva Inc. (NASDAQ: INVA). Learn more about these stocks by accessing their free trade alerts at:
PFPT: 64.66 (+0.53), INVA: 11.38 (-0.02), WDAY: 73.79 (+1.19), FTNT: 32.10 (+0.42)
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.38 (-0.02), TBPH: 23.00 (+0.05), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.38 (-0.02)
Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks Equity Research - Zacks Investment Research - Wed May 25, 10:21AM CDT
GlaxoSmithKline (GSK) and partner Innoviva reported positive headline data from a phase IIIb chronic obstructive pulmonary disease study on Relvar Ellipta.
INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'
Marketwire Canada - Tue May 24, 5:01AM CDT
Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice
INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:14AM CDT
Glaxo (GSK) and Innoviva (INVA) have announced results of two pre-specified analyses from the SUMMIT study on Breo Ellipta.
INVA: 11.38 (-0.02), ANIP: 58.12 (+0.59), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22)
GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI'
in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy. INVA: 11.38 (-0.02), GSK: 43.34 (-0.31)
